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Prognostic Value of Cross-sectional Anthropometric Indices on Short-term
Risk of Mortality in Human Immunodeficiency Virus-infected Adults in
Abidjan, Côte d’Ivoire
K. Castetbon,1–3 X. Anglaret,3,4 S. Touré,3 G. Chêne,1 T. Ouassa,3,4 A. Attia,3,5 T. N’Dri-Yoman,3,5 D. Malvy,1,6 R.
Salamon,1,3 and F. Dabis1,3 for the COTRIMO-CI Study Group
In sub-Saharan Africa where weight loss is very difficult to estimate, cross-sectional anthropometric indicators
could be useful to predict human immunodeficiency virus (HIV)-associated mortality. The study objective was to
look for threshold values of baseline body mass index, arm muscle circumference, and fat mass to predict the
risk of death in HIV-infected adults included in a 1996–1998 trial of early cotrimoxazole chemoprophylaxis in
Abidjan, Côte d’Ivoire (COTRIMO-CI–ANRS 059 trial). The authors graphically determined if consecutive
anthropometric categories with the closest hazards ratios of the risk of death could be clustered to obtain a
unique threshold that distinctly separated two categories. When the threshold values were determined, the
authors estimated the hazards ratio of mortality of this two-category model. A significant increase of mortality
was observed for a body mass index of ≤20.3 in men (hazards ratio = 2.6; 95% confidence interval (CI): 1.4, 5.0)
and of ≤18.5 in women (hazards ratio = 2.2; 95% CI: 1.05, 4.5) and for a fat mass of ≤6% in men (hazards ratio
= 4.6; 95% CI: 2.3, 9.4) and of ≤18% in women (hazards ratio = 2.4; 95% CI: 1.2, 4.9). No simple threshold could
be identified for arm muscle circumference. In Côte d’Ivoire where chemoprophylaxis of opportunistic infections
has recently been recommended to be widely initiated on clinical criteria, such thresholds may help to screen
patients with higher risks of mortality. Am J Epidemiol 2001;154:75–84.
body mass index; HIV infections; survival; weight loss
Received for publication May 10, 2000, and accepted for publica-
tion November 29, 2000.
Abbreviations: CI, confidence interval; COTRIMO-CI, cotrimoxa-
zole chemoprophylaxis in Abidjan, Côte d’Ivoire; HIV, human immun-
odeficiency virus; HIV+, HIV infected.
1 INSERM U.330, Université Victor Segalen Bordeaux 2,
Bordeaux, France.
2 Centre IRD de Petit-Bassam, Abidjan, Côte d’Ivoire.
3 Programme PAC-CI, Abidjan, Côte d’Ivoire.
4 Centre de Diagnostic et de Recherche sur le SIDA et les
Infections Opportunistes, CHU de Treichville, Abidjan, Côte d’Ivoire.
5 Service de Gastro-Entérologie, CHU de Yopougon, Abidjan,
Côte d’Ivoire.
6 Centre René Labusquière, Université Victor Segalen Bordeaux
2, Bordeaux, France.
Reprint requests to Dr. Katia Castetbon, INSERM U.330,
Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076
Bordeaux Cedex, France (e-mail: Katia.Castetbon@isped.u-bor-
deaux2.fr).
Weight loss is part of the definition of the human immun-
odeficiency virus (HIV) wasting syndrome (1) and is the
unique nutritional criterion routinely used in international
classification systems for HIV infection (2–4). Several stud-
ies have shown that weight loss strongly predicts morbidity
and mortality in HIV-infected (HIV+) adults (5–8). All these
studies were performed on patients from industrialized
countries with quite advanced immunodepression (mean
CD4+ lymphocyte count from 86 to 281/mm3) (5). Most
were performed on homosexual men (5, 7, 8) and only one
on women (6).
In sub-Saharan Africa, weight loss is often difficult to
estimate for HIV+ patients. When attending health care facil-
ities for the first time, most patients either are unaware of
their usual body weight or report unverifiable usual body
weight. Because the CD4+ lymphocyte count and HIV viral
load are also rarely available, it should be of particular inter-
est to identify other anthropometric indicators than weight
loss that could help to evaluate the risk of mortality and that
could be easily measured.
Body mass index is the unique anthropometric indicator
other than weight loss that has already been related to mor-
tality in HIV+ homosexual men in the Netherlands (9) and in
HIV+ women in Rwanda (10). However, to our knowledge,
this association was never confirmed in other African women
and never assessed among African men. Furthermore, body
mass index, like weight loss, reflects the global nutritional
status (11) but not the early and specific consequences of
HIV infection on body components, namely, a reduction of
fat mass (12, 13), accompanied in some patients by a deple-
tion of fat-free mass (14, 15). Fat mass and fat-free mass
could thus be hypothesized to better and earlier predict mor-
tality than weight loss or body mass index. Several previous
studies using complex and expensive techniques (bioelectric
impedance analysis, total body-potassium counting) to mea-
sure body components in a limited series of patients have
supported this hypothesis (14, 16, 17). However, this remains
to be confirmed in larger studies. Should these studies be per-
formed in Africa, simpler methods that could be routinely
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implemented by clinicians (such as skinfold thicknesses and
arm muscle circumference) should be used to measure body
components.
We report an analysis of the prognostic value of body
mass index, arm muscle circumference, and skinfold thick-
nesses on mortality in HIV+ men and women included in a
randomized placebo-controlled trial of prevention of oppor-
tunistic infections by trimethoprim-sulfamethoxazole in
Abidjan, Côte d’Ivoire. This trial has demonstrated the effi-
cacy of such a prophylaxis initiated at an early stage of HIV
disease in African patients (18).
MATERIALS AND METHODS
Patients
The present study was performed on patients included in
a double-blind placebo-controlled trial conducted in
Abidjan, Côte d’Ivoire, from April 1996 to March 1998.
This study assessed the efficacy of cotrimoxazole prophy-
laxis in reducing severe clinical events in HIV-infected
adults recruited at early stages of HIV-1 infection 
(COTRIMO-CI–ANRS 059 trial). The study population and
medication have been described elsewhere (18). In brief,
patients whose HIV infection was diagnosed in routine con-
sultations at five urban community health centers of Abidjan
were included if they met the following criteria: aged 18
years or more, HIV-1 or HIV-1 plus HIV-2 dual infection,
clinical stage 2 or 3 of the World Health Organization stag-
ing system for HIV infection and disease (2), and written
consent. Reasons for exclusion were pregnancy, breastfeed-
ing, prior history of intolerance to any sulfonamide, hemo-
globin level less than 7 mg/dl, platelet count less than
75,000/mm3, absolute neutrophil count less than 750/mm3,
and renal or hepatic failure. The lymphocyte CD4+ count
was not used as an inclusion/exclusion criterion but was
documented by flow cytometry after randomization in all
included patients. Subjects were randomly assigned to
receive daily either cotrimoxazole (800 mg of sulfamethox-
azole and 160 mg of trimethoprim) in a single tablet or a
matching placebo. No patient had a history of chemopro-
phylaxis against tuberculosis or any other opportunistic
infections at enrollment in the trial. Before the trial and 
during trial follow-up, no patients received antiretroviral
treatment.
Measurements
Baseline demographic, clinical, and biologic data were
recorded through standardized questionnaires, including a
physical examination and measurement of the CD4+ count.
Three physicians, trained by one nutritionist, performed
anthropometric measurements in a standardized fashion:
weight (measured to the nearest 0.2 kg, on an electronic
scale, patient dressed but without shoes); height (measured
to the nearest 1 cm, on a wall scale, patient without shoes
and with joined feet); mid-upper arm circumference (mea-
sured to the nearest 5 mm, on the half left arm); and skinfold
thickness at four sites (bicipital, tricipital, subscapular, and
suprailiac) measured to the nearest 0.2 mm with a caliper
(SiberHegner & Cie. S.A., Miribel, France). We then com-
puted the body mass index as the ratio of weight (kg) to
height (m) squared, the arm muscle circumference as the
mid-upper arm circumference – × the tricipital skinfold
(mm) (19), and the percentage of fat mass according to the
Durnin-Womersley equation using values of the above four
skinfold thicknesses, age, and gender (20). During the initial
interview, patients were systematically asked for their usual
body weight defined as their weight before they became
symptomatic for HIV disease. For patients who self-
reported a usual body weight, the percentage of weight loss
was defined as 100 × (usual body weight – inclusion body
weight)/usual body weight.
Follow-up
After randomization, patients were asked to attend
monthly scheduled visits. Within the interval, they were
asked to visit the medical team at the trial center as soon as
they had medical problems. All medications, explorations,
hospitalizations, and transportation were offered on a free
basis. All clinical events (including death) were referred for
independent review by an event documentation committee
blinded to the treatment group. Vital status was systemati-
cally investigated for patients who did not keep scheduled
appointments through home visits and telephone calls and by
screening the obituary sections of the national newspapers.
Statistical analysis
In this report, we analyzed patients with complete anthro-
pometric data at entry into the study and available follow-up
data. The follow-up duration was defined as the interval
between the date of inclusion and the date of death, or the
date of the last contact with the trial team if before the end
of the trial (March 17, 1998), or the date of the end of the
trial if a contact with the trial team was recorded after March
17, 1998. Comparisons of means were performed using the
Student t test or the Student t test for unequal variances if
Bartlett’s test for the equality of variances was <0.05. For
comparisons of proportions, the chi-squared test was used.
Subsequent analyses were performed with men and women
separately because of the inherent difference of the distribu-
tion in body components (19).
The following nonanthropometric baseline characteristics
were studied in relation to the risk of death through univari-
ate analyses by gender using proportional hazards models:
age; any paid activity; school level (patients never schooled
or at primary school level vs. patients with at least sec-
ondary school level); CD4+ count (CD4+ of <200/mm3,
200–500/mm3, and >500/mm3); World Health Organization
clinical stages; and treatment groups (cotrimoxazole vs.
placebo). Subsequent multivariate analyses included all
baseline nonanthropometric variables related to mortality in
the above univariate analyses with a p < 0.25.
To determine the thresholds of substantial increase in the
risk of death, we used the analysis strategy presented in fig-
ure 1 for each anthropometric indicator and each gender.
Our strategy combined an approach derived from cluster
p
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FIGURE 1. Analysis strategy for determination of anthropometric thresholds to distinguish survival in human immunodeficiency virus-infected
adults in Abidjan, Côte d’Ivoire, 1996–1998. AI, anthropometric indicator; HR, hazards ratio estimated by the proportional hazards model in ref-
erence to the anthropometric category with the highest values and adjusted on covariates; CI, confidence interval.
analysis (21) and from the principles of modeling in a prog-
nosis context (22). After dividing the anthropometric indi-
cator into four categories, each of which contained an equal
number of deceased patients, we estimated the hazards ratio
for each dummy variable thus created using as the reference
class the category with the highest value of the indicator.
Graphical representation of the hazards ratio was used to
estimate whether the increase in the risk of death was con-
stant or if a substantial increase of this risk was appreciable
between two categories. When the latter was the case, the
closest categories were combined to obtain two categories,
the anthropometric threshold of mortality being defined by
the highest value of the category not containing the refer-
ence values. The Akaike Information Criterion was used to
compare the fit of the data for the models with two and four
categories. When no threshold could be determined because
of a log-linear relation (case 1 in figure 1) or nonconsecutive
clustering (case 2 in figure 1), the results of the model that
included the anthropometric indicator as a continuous vari-
able were presented. When no threshold could be defined
because the four-category model best fit the data (case 3 in
figure 1), the results of this latter model were presented.
When a threshold could be determined (case 4 in figure 1),
we presented the survival using Kaplan-Meier life tables
according to the baseline nutritional status around this
threshold.
RESULTS
Baseline characteristics
From April 23, 1996, to March 17, 1998, 545 patients
were assigned at random to the COTRIMO-CI–ANRS 059
trial (18), of whom 35 (6 percent) were excluded from the
analyses for the present study: four because they were sub-
sequently confirmed to be HIV-2+ only, 16 because they had
incomplete anthropometric data at inclusion, and 15 because
they had no available follow-up information. Follow-up data
and data on the documentation of vital status of patients
enrolled in the ANRS 059 trial have been previously reported
elsewhere (18). Among the 510 patients analyzed in the pres-
ent study, 86 (17 percent) were known to be deceased at trial
termination, 389 (76 percent) had been seen at least once by
the trial team within the last month, and for the remaining 35
(7 percent) the time from the last contact with the trial team
to the trial termination was more than 1 month.
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Among the 510 patients analyzed, 58 percent were
women, 50 percent had a paid activity, and 56 percent were
never schooled or had reached a primary school level. The
mean age was 32.8 (standard deviation, 8.9) years. At entry
into the trial, 34 percent of the patients were classified at
World Health Organization clinical stage 2, 60 percent at
stage 3, and 6 percent at stage 4. The mean CD4+ lympho-
cyte count was 325 (standard deviation, 263)/mm3, while 39
percent of the patients had a CD4+ lymphocyte count of
<200/mm3, 41 percent had a count of 200–500/mm3, and 20
percent had a count of >500/mm3.
The following baseline characteristics differed signifi-
cantly between men and women: age (36.2 years vs. 30.4
years, p < 10–4), percentage of patients with paid activity 
(64 percent vs. 40 percent, p < 10–4), percentage who were
never schooled or at a primary school level (41 percent vs.
68 percent, p < 10–4), and mean CD4+ count (275/mm3 vs.
360/mm3, p  0.0003). The proportion of patients at World
Health Organization stages 2, 3, and 4 did not differ signif-
icantly between men and women (stage 2: 30 percent vs. 37
percent; stage 3: 62 percent vs. 58 percent; p  0.07). As
expected, distributions of demographic, biologic, and clini-
cal data were comparable at baseline between randomiza-
tion groups: cotrimoxazole or placebo (data not shown)
(18).
Baseline anthropometric characteristics are described in
table 1. Weight loss could be estimated in 75 percent of
patients (men: 91 percent, women: 64 percent; p < 10–4).
Cross-sectional nutritional indicators recorded at baseline
were comparable in patients who did not know their usual
body weight and in those who did, with the exception of
mean weight (50.7 kg vs. 53.3 kg; p  0.02) and mean body
mass index (19.9 vs. 20.7; p  0.01) in women, suggesting
that women who did not know their usual body weight pre-
sented a poorer nutritional status than women who knew it.
Although 90 percent of patients with known usual body
weight were considered to have weight loss, moderate or
severe malnutrition was infrequent in this group of patients:
only 2 percent had severe thinness (body mass index of
<16), 79 percent had a normal corpulence (body mass index
of ≥18.5), and 70 percent had a normal mid-upper arm cir-
cumference of >243 mm for men and of >232 mm for
women according to World Health Organization standards
(19). The mean reported weight loss was significantly
higher in men than in women. All other anthropometric vari-
ables were distributed as expected according to gender: the
mean body mass index was comparable for men and
women, the mean arm muscle circumference was higher in
men than in women, and the mean fat mass was lower in
men than in women (table 1).
Prognostic value on survival of thresholds of nutritional
indicators
Covariates. The 510 patients included in the analysis
experienced a mean follow-up of 9.9 months (421 person-
years). During this follow-up period, 86 patients died, 51
men and 35 women. The following variables were related to
survival with a statistical significance of less than 0.25: in TA
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men, the CD4+ count (compared with the CD4+ count of
>500/mm3: hazards ratio  6.2 (95 percent CI: 0.8, 47.6) for
a CD4+ count of 200–500/mm3, p  0.08; and hazards ratio 
19.2 (95 percent CI: 2.6, 140.2) for a CD4+ count of
<200/mm3, p  0.004); World Health Organization clinical
stage (compared with stage 2: hazards ratio  1.9 (95 per-
cent CI: 0.9, 3.8), p  0.08, for stage 3; and hazards ratio 
2.9 (95 percent CI: 1.1, 7.8), p  0.03, for stage 4); and age
(hazards ratio  1.2 (95 percent CI: 0.9, 1.6) for 10 years
higher, p  0.17). In women, the respective values were as
follows: CD4+ count (hazards ratio  4.8 (95 percent CI:
0.6, 39.2), p  0.14, for a CD4+ count of 200–500/mm3, and
hazards ratio  37.2 (95 percent CI: 5.0, 276.7), p < 10–3,
for a CD4+ count of <200/mm3) and World Health
Organization clinical stage (hazards ratio  2.6 (95 percent
CI: 1.1, 6.1), p  0.03, for stage 3, and hazards ratio  8.7
(95 percent CI: 2.7, 27.7), p < 10–3, for stage 4). The statis-
tical significance of the relation between treatment group
(cotrimoxazole vs. placebo) and mortality was 0.83 in men
and 0.39 in women. The treatment group was thus not taken
into account in subsequent multivariate analyses.
Weight loss. In a comparison of men with known usual
body weight and no weight loss or a weight loss of ≤5 per-
cent (n  60), the hazards ratios of death were 1.8 (95 per-
cent CI: 0.7, 4.5) (p  0.19) for men with a >5–≤10 percent
weight loss (n  55) and 2.9 (95 percent CI: 1.2, 6.8) (p 
0.01) for men with a weight loss of >10 percent (n  80). In
women, the hazard ratios were 6.9 (95 percent CI: 0.6, 83.9)
(p  0.13) for a weight loss of >5–≤10 percent (n  30) and
18.6 (95 percent CI: 1.8, 189.8) (p  0.01) for a weight loss
of >10 percent (n  113). In these mutivariate analyses, the
CD4+ count remained significantly related to survival. For
example, in men, the hazards ratio  7.0 (95 percent CI: 0.9,
54.4) (p  0.06) for a CD4+ count of 200–500/mm3; the haz-
ards ratio  18.9 (95 percent CI: 2.5, 142.3) (p  0.004) for
a CD4+ count of <200/mm3.
Body mass index, arm muscle circumference, and fat
mass in men. Figure 2 shows the relation between the
hazards ratio of death and the median value of body mass
index (figure 2, top), arm muscle circumference (figure 2,
middle), and fat mass (figure 2, bottom). We further grouped
into a unique category the first three categories for body
mass index and arm muscle circumference and for the last
three categories for fat mass. This allowed us to define only
two categories of patients for each nutritional indicator, dis-
tinguished by the following thresholds: 20.3 for body mass
index, 250 mm for arm muscle circumference, and 6 percent
for fat mass. Comparison of the log-likelihood, weighted for
the number of parameters, of the two-category models ver-
sus the four-category models showed that the two-category
models best fit the data (body mass index: –232.5 vs.
–234.0; arm muscle circumference: –235.4 vs. –237.2; and
fat mass: –230.3 vs. –230.7, respectively). When comparing
survival acording to these thresholds (table 2), we found that
body mass index and fat mass were significantly related to
survival (hazards ratio  2.6 (95 percent CI: 1.4, 5.0) for a
body mass index of ≤20.3 and hazards ratio  4.6 (95 per-
cent CI: 2.3, 9.4) for a fat mass of ≤6 percent), while the
relation did not reach significance for an arm muscle cir-
cumference of ≤250 mm (hazards ratio  2.0 (95 percent
CI: 0.95, 4.1)). In all of these multivariate analyses, the
CD4+ lymphocyte count remained significantly related to
survival (e.g., in the model with body mass index, the haz-
ards ratio  5.9 (95 percent CI: 0.77, 45.5) for a CD4+ count
of 200–500/mm3 (p  0.09); the hazards ratio  17.9 (95
percent CI: 2.4, 132.1) for a CD4+ count of <200/mm3 (p 
0.005)), unlike the other studied covariates (age and World
Health Organization clinical stage). When performing mul-
tivariate analysis that included body mass index, arm mus-
cle circumference, fat mass, and the covariates, we found
that the fat mass threshold provided the best prediction of
the risk of death (hazards ratio  3.7; 95 percent CI: 1.8,
7.7), whereas the body mass index (hazards ratio  1.9; 95
percent CI: 0.90, 4.20) and arm muscle circumference (haz-
ards ratio  1.3; 95 percent CI: 0.55, 2.97) thresholds were
not associated with mortality.
Body mass index, arm muscle circumference, and fat
mass in women. It was not possible to determine a thresh-
old for arm muscle circumference (figure 3, middle),
because the closest categories were the first and the third.
The model that included arm muscle circumference as a
continuous variable showed that it was not associated with
survival (hazards ratio  0.91; 95 percent CI: 0.76, 1.09) 
(p  0.31 for 10 mm higher). For body mass index (figure
3, top) and fat mass (figure 3, bottom), we grouped the first
two classes and the corresponding thresholds were 18.5 per-
cent and 18 percent, respectively. For body mass index, the
weighted log-likelihoods were –156.5 for the model with
two nutritional categories and –158.4 for the model with
four nutritional categories; for fat mass, they were –155.5
and –157.4, respectively. Survival analyses showed that we
could distinguish the survival of women when classifying
them according to the baseline nutritional values around the
determined thresholds above (table 2). The CD4+ count
remained significantly associated with survival in these
models (e.g., in the model with body mass index: the haz-
ards ratio  5.0 (95 percent CI: 0.61, 45.5) for a CD4+ count
of 200–500/mm3 (p  0.13); the hazards ratio  32.0 (95
percent CI: 4.2, 242.7) for a CD4+ count of <200/mm3 (p 
0.001)), unlike the World Health Organization stage. In mul-
tivariate analysis that included the body mass index, fat
mass, and covariates, the fat mass threshold was the best
predictor of mortality (hazards ratio  2.0 (95 percent CI:
0.99, 4.36)).
DISCUSSION
To our knowledge, this is the first study that assessed the
prognostic value of anthropometric indicators on survival in
African HIV-1-infected men and women. Our population
was part of a group of HIV-1-infected adults included in a
trial of early cotrimoxazole primary chemoprophylaxis (18).
We analyzed available data from 94 percent of the patients
enrolled in this trial and followed up during a mean of 10
months. We found that the nutritional indicators at baseline
had a prognostic value on survival independently from the
CD4+ count measured at the same time. We determined lim-
its for each nutritional variable that were correlated with
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FIGURE 2. Relation between hazards ratios of death (Napierian logarithmic scale) and baseline values of body mass index (top), arm mus-
cle circumference (middle), and fat mass (bottom) in human immunodeficiency virus-infected men in Abidjan, Côte d’Ivoire, 1996–1998 (n =
214). The hazards ratios of death were estimated from proportional hazards models that included each class of the anthropometric variables
except the highest and that were adjusted for the lymphocyte CD4+ count at baseline divided into three classes, the World Health Organization
clinical stage, and the age (for 10 years higher). Bars, confidence interval.
survival: 20.3 for body mass index in men and 18.5 in
women and 6 percent for fat mass in men and 18 percent in
women. The arm muscle circumference in men and in
women did not have a prognostic value on survival in our
population.
Interpretation of our findings must take into account sev-
eral issues. First, the reference for each anthropometric vari-
able was defined as the category containing the highest val-
ues. Our findings thus closely depend on our population.
Included patients were screened according to inclusion cri-
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teria in a randomized clinical trial and, thus, may not repre-
sent the population of HIV-infected adults living in Abidjan.
However, they were recruited in routine ambulatory consul-
tations of urban community health centers and may, thus, be
considered as more representative of the unscreened popu-
lation of symptomatic HIV-infected adults looking for care
than HIV-infected inpatients hospitalized with advanced
HIV disease. Second, the context of a therapeutic trial, in
which half of the patients received cotrimoxazole and half a
placebo, is a potential limit. However, we verified that there
was no interaction on mortality between the treatment
groups and the nutritional status at inclusion. Third, our ref-
erence was the nutritional measurement at inclusion in a
prevalent cohort, without information on the date of infec-
tion. However, we measured the CD4+ lymphocyte count at
baseline and verified that the anthropometric indicators
were associated with the risk of mortality independently
from the CD4+ count. Fourth, our analysis compares groups
of patients classified at a given time and does not estimate
prospectively the change in the risk of death according to
the evolution of the anthropometric indicators, especially
the changes below or above the defined thresholds. For this
purpose, treatment of the anthropometric variables as time-
dependent variables would be required (9). However, as an
initial step and from a pragmatic standpoint, our study based
on the initial measure is justified as it corresponds to the sit-
uation of most African settings where no follow-up data are
available. Further studies should now validate these anthro-
pometric thresholds in other samples of patients.
In our population, we verified that weight loss had a prog-
nostic value on mortality, although 9 percent of men and 36
percent of women did not know their usual body weight.
This difference possibly reflects a lower access to care in
women than in men. In patients with known usual body
weight, the estimated mean weight loss was higher in
women than in men, although their body mass index was
comparable and the CD4+ count was higher in women, this
latter being related to their less advanced stage of HIV infec-
tion than men. We supposed that women overestimated their
usual body weight, possibly in reference to a weight
recorded during or immediately after a previous pregnancy.
These observations emphasize the need for cross-sectional
anthropometric references other than weight loss, inasmuch
as we observed that women who did not know their usual
body weight were at a higher risk of malnutrition. Although
the duration of follow-up was shorter in our study, our find-
ings are comparable with those of three previous studies
mainly performed in homosexual men from the United
States. A first one (8) showed that mortality was 2.5 times
higher in patients who experienced a weight loss of >10 per-
cent than in patients with no weight loss (p ≤ 0.001). In a
second one (7), the median survival times decreased signif-
icantly when weight loss increased (p  0.0001). In a third
one (5), patients with a weight loss of >10 percent had a
TABLE 2. Kaplan-Meier estimation of the probability of survival according to the limits of anthropometric variables and risk 
estimates in proportional hazards models in human immunodeficiency virus-infected adults in Abidjan, Côte d’Ivoire, 1996–1998
(n = 510)
Survival at
Body mass index (kg/m2)
Men
≤20.3
>20.3
Women
≤18.5
>18.5
Arm muscle circumference (mm)¶
Men
≤250
>250
Fat mass (%)
Men
≤6
>6
Women
≤18
>18
120
74
72
224
149
65
21
193
81
215
6 months
82.8
93.1
92.7
96.1
84.0
95.1
55.0
90.9
91.2
96.8
74.3, 88.7
85.3, 96.8
83.3, 96.9
92.0, 98.1
76.6, 89.1
85.5, 98.4
31.3, 73.5
85.5, 94.3
81.5, 96.0
93.0, 98.6
2.62
2.17
1.97
4.63
2.43
66.8
87.0
66.4
91.2
70.8
86.4
40.7
79.4
66.0
91.9
56.6, 75.3
76.9, 92.8
50.7, 78.1
85.1, 94.9
61.7, 78.1
73.4, 93.4
18.0, 62.5
72.1, 85.1
50.9, 77.4
85.9, 95.4
0.004
0.04
0.07
<10–3
0.01
Probability
No.* 12 months
95% CI Probability 95% CI
Hazards
ratio
p
value95% CI†
1.37, 5.00‡
1.05, 4.47§
0.95, 4.08‡
2.29, 9.38‡
1.21, 4.88§
* Number of patients at risk at inclusion.
† CI, confidence interval.
‡ Adjusted for lymphocyte CD4+ count in three classes, the World Health Organization clinical stage, and the age.
§ Adjusted for the lymphocyte CD4+ count and the World Health Organization clinical stage.
¶ No threshold has been determined in women.
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FIGURE 3. Relation between hazards ratios of death (Napierian logarithmic scale) and values of body mass index (top), arm muscle circum-
ference (middle), and fat mass (bottom) in human immunodeficiency virus-infected women in Abidjan, Côte d’Ivoire, 1996–1998 (n = 296). The
hazards ratios of death were estimated from proportional hazards models that included each class of the anthropometric variables except the
highest and that adjusted for the lymphocyte CD4+ count at baseline divided into three classes and the World Health Organization clinical stage.
Bars, confidence interval.
mortality 8.3 times higher, on average, than patients with a
weight loss of ≤10 percent (p < 0.002). All of these estima-
tions were adjusted for CD4+ count, as ours. This underlines
the notion that nutritional status is associated with progno-
sis, independently from immune status in HIV infection, and
the interest of a nutritional component in a global biologic
and clinical evaluation.
The main objective of our study was to evaluate the con-
tribution of cross-sectionally measured anthropometric indi-
cators other than weight loss to the prediction of survival. Of
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the studied nutritional indicators, only body mass index was
previously assessed with this aim in a study performed in
HIV-infected women from Rwanda (10). In this previous
study, women with a body mass index of ≤21 experienced a
mortality rate 2.3 times higher, on average, than did women
with a body mass index of >21. For a comparable hazards
ratio of death, our threshold of body mass index in women
was surprisingly lower (and closer to the reference value in
the non-HIV population (19)), while our threshold in men
was comparable with the threshold found in the Rwandese
women. One could formulate the following hypothesis to
explain this fact: women in our study had a better initial
immunologic status than did men and, although body mass
index was globally shown to predict mortality indepen-
dently from the CD4+ count, the level of a calculated thresh-
old probably depends on the stage of the disease in a
selected population. As CD4+ counts were not performed in
the Rwandese study, we could not compare the immuno-
logic status of the population of the two studies. However,
in our study, the differences between men and women in the
initial immune stages and in the calculated body mass index
thresholds related with mortality support this hypothesis.
Despite this limitation, body mass index is clearly con-
firmed to be an easy-to-measure alternative to weight loss to
predict survival.
The two other nutritional indicators assessed in this study
remain of interest. Although the depletion of body cell mass
is usually considered more critical for survival than the
depletion of fat mass (14), the increased risk of death for
impaired arm muscle circumference was lower than for
reduced fat mass, and the association of the arm muscle cir-
cumference value with survival was not significant.
Moreover, when performing analyses with body mass index,
arm muscle circumference, and fat mass together, we found
that fat mass was the most strongly related to survival.
These findings could be explained by the relatively early
stage of HIV disease in our population, in whom the deple-
tion of fat mass could have been more important than the
depletion of fat-free mass, as previously described (12).
Moreover, the anthropometric estimation of the fat-free
mass imperfectly reflects body cell mass, which was evalu-
ated through accurate total 40K in the study showing the rela-
tion between survival and nutritional status (14). Statistical
analyses performed with the bone-free arm muscle area (23)
instead of the arm muscle circumference showed the same
findings as in our sample. Finally, a low percentage of fat
mass could be as prejudicial to survival in HIV-infected
adults as a low body cell mass level, and fat mass could thus
be more interesting to monitor at early stages of HIV disease
than arm muscle circumference. In settings where calipers
are not easily accessible, body mass index evaluation
remains useful.
We observed that distributions of arm muscle circumfer-
ence and fat mass values differed greatly between men and
women, and we found very different thresholds predicting
survival in men and women for fat mass (6 percent vs. 18 per-
cent). These findings are compatible with the present knowl-
edge about gender differences in general and HIV-associated
nutritional alterations (24, 25). However, the observed differ-
ence in the fat mass threshold between genders could also
have been partly related to the highest level of immuno-
depression of men in our population as stated above for body
mass index. The estimated fat mass threshold in men was par-
ticularly low (6 percent) in the limit acceptable with survival.
With one quarter of the men in our study presenting fat mass
less than 7.7 percent (table 1), these levels do not seem excep-
tional. Even if our results were adjusted for CD4+ count, it
remains to elucidate whether different thresholds should be
used at different states of immunodepression to better predict
mortality.
Given that it remains unclear whether an easy-to-apply
nutritional intervention could change the course of HIV
infection (26), our objective was first to provide useful tools
for physicians working in sub-Saharan Africa to better eval-
uate the risk of HIV-related mortality. Despite the limita-
tions of the methods, the proposed thresholds have been
shown to have a significant prognostic value on survival in
our population. If confirmed in other populations, measure-
ment of these anthropometric indicators could become part
of the routine clinical evaluation of HIV+ patients examined
for the first time in sub-Saharan Africa, and the proposed
thresholds could contribute to the decision to initiate some
interventions, such as chemoprophylaxis of opportunistic
infections, based on clinical criteria, whether or not the
CD4+ count is available (18).
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